UNITED KINGDOM
INFORMATION AND ENQUIRIES

 

PUBLIC INFORMATION

This content of this page is intended to provide information for members of the public in the United Kingdom.

The Medicines and Healthcare products Regulatory Agency (MHRA) website contains easily accessible information about licensed medicines available in the United Kingdom.
 

If you click on the links below you will be redirected to the electronic Medicines Compendium (eMC) website with the Product Information Leaflet (PIL) and Summary of Product Characteristics (SPC). The eMC is a non-KalVista website.

Medicine: EKTERLY^® (sebetralstat) PIL and SPC

REPORTING OF ADVERSE EVENTS

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or by searching for MHRA Yellow Card in Google Play or Apple App Store. Adverse events should also be reported to KalVista UK on 0800 066 8200 or medinfoeurope@kalvista.com.

FURTHER INFORMATION

For medical information and product complaint reporting, please contact KalVista UK at:
medinfoeurope@kalvista.com
Tel: 0800 066 8200

 

GENERAL INFORMATION / CONTACT DETAILS

For General Enquiries: ukinfo@kalvista.com
KalVista Pharmaceuticals Ltd, Porton Science Park, Bybrook Road, Porton Down, Salisbury, SP4 0BF

---

DISCLOSURES

UK Healthcare Professionals, other relevant decision makers and healthcare organisations
In accordance with the ABPI Code of Practice, we disclose transfers of value made to UK healthcare professionals, other relevant decision makers and healthcare organisations. These disclosures are published annually (covering the previous calendar year) on the Disclosure UK website. Further information can be found here:
Disclosure UK

UK Patient Organisations
In accordance with the ABPI Code of Practice, details of support provided to patient organisations are published annually on our website. Contributions to patient organisations are outlined below:
2025 Disclosure for Patient Organisations
2025 Methodological Notes

UK Patients, Journalists and Members of the Public
In accordance with the ABPI Code of Practice, we disclose payments for certain contracted services made to patients, journalists and members of the public on an aggregate basis.
2025 Disclosure for Members of Public, Patients and Journalists
2025 Methodological Notes

Developed and funded by KalVista Pharmaceuticals
MAT-EKT-GB-0019 / prepared June 2026.